The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Baryshev A.G.

Research Institute — Ochapovsky Regional Clinic Hospital №1 of Healthcare Ministry of Krasnodar Region, Krasnodar, Russia;
Chair of Surgery №1, Advanced Training Faculty, Kuban State Medical University, Krasnodar, Russia

Follow-up of long-term trastuzumab use in advanced gastric cancer with HER2 receptor hyperexpression

Authors:

Baryshev A.G.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2013;2(4): 67‑69

Read: 763 times

Download PDF (RU)
Contact the author
Table of contents

FOLLOW-UP OF LONG-TERM TRASTUZUMAB USE IN ADVANCED GASTRIC CANCER WITH HER2 RECEPTOR HYPEREXPRESSION
FOLLOW-UP OF LONG-TERM TRASTUZUMAB USE IN ADVANCED GASTRIC CANCER WITH HER2 RECEPTOR HYPEREXPRESSION

To cite this article:

Baryshev AG. Follow-up of long-term trastuzumab use in advanced gastric cancer with HER2 receptor hyperexpression. P.A. Herzen Journal of Oncology. 2013;2(4):67‑69. (In Russ.)

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

The paper describes a case of long-term use of trastuzumab in combination with a few successive lines of chemotherapy (CT) in a patient with advanced gastric cancer (GC). Trastuzumab, a recombinant humanized monoclonal antibody, has proven its efficacy when used in combination with CT as first-line treatment for the patient with advanced GC with HER2 hyperexpression.

Keywords:

advanced gastric cancer
HER2
transtuzumab

Authors:

Baryshev A.G.

Research Institute — Ochapovsky Regional Clinic Hospital №1 of Healthcare Ministry of Krasnodar Region, Krasnodar, Russia;
Chair of Surgery №1, Advanced Training Faculty, Kuban State Medical University, Krasnodar, Russia

Close metadata

References:

  1. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 2006; 24: 3137-50.
  2. Cunningham S.C., Kamangar F., Kim M.P. et al. Survival after gastric adenocarcinoma resection: Eighteen-year experience at a single institution. J. Gastrointest. Surg. 2005; 9: 718-25.
  3. Pyrhönen S., Kuitunen T., Nyandoto P. et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer. 1995; 71: 587.
  4. Glimelius B., Ekström K., Hoffman K. et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. 1997; 8:163.
  5. Kang J.H., Lee S.I., Lim do H. et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J. Clin. Oncol. 2012; 30 (13): 1513-8.
  6. Comis R. Integration of chemotherapy into combined modality treatment of solid tumours. Cancer Treat. Rev. 1974; 1: 221-3.
  7. Beer M., Cocconi G., Cecci G. et al. A phase II study of cisplatin in advanced gastric cancer. Eur. J. Cancer Clin. Oncol. 1983; 19: 717-20.
  8. Macdonald J.S., Steele G.J., Gunderson L.L. Cancer of the Stomach. In: DeVita V.T., Hellman S., Rosenberg S.A., eds. Cancer principles and practice of oncology. Philadelphia: Lippincott; 1989: 765-97.
  9. Wagner A.D., Grothe W., Haerting J. et al. Chemotherapy in advanced gastric cancer:a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. 2006; 24: 2903-9.
  10. Glimelius B., Ekstrom K., Hoffman K. et al. Randomized comparison between chemotherapy plus best supportive care in advanced gastric cancer. Ann. Oncol. 1997; 8: 163-8.
  11. Tebbutt N., Sournina T., Strickland A. et al. ATTAX: Randomized phase II study evaluating weekly docetaxel-based chemotherapy combinations in advanced esophagogastric cancer: final results of an AGITG trial (abstract). J. Clin. Oncol. 2007; 25: 204s.
  12. Yun J., Lee J., Park S.H. et al. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. Eur. J. Cancer. 2010; 46: 885.
  13. Ridwelski K., Fahlke J., Kettner E. et al. Docetaxel-cisplatini (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study (abstract). J. Clin. Oncol. 2008; 26: 216s.
  14. Cunningham D., Starling N., Rao S. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 2008; 358 (1): 36-46.
  15. Van Cutsem E., Moiseyenko V.M., Tjulandin S. et al. Phase 3 study of docetaxel and cisplatin plus Fluorouracil as first-line therapy for advanced gastric cancer:a report of the V-325 Study Group. J. Clin. Oncol. 2006; 24: 4991-7.
  16. Okines A.F., Normal A.R., McCloud P. et al. Meta-analysis of the REAL-2 and ML17032 trials:evaluating capecitabine-based combination chemotherapy and infused 5-ftorouracil-Based combination chemotherapy for the treatmend of advanced oesophagogastric cancer. Ann. Oncol. 2009; 20: 1529-34.
  17. Beretta E., Di Bartolomeo M., Buzzoni R. et al. Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition. Tumori. 2006; 92 (5): 379-83.
  18. Enzinger P.C., Burtness B., Hollis D. et al. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (SCF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J. Clin. Oncol. 2010; 28: 302s; abstr. 4006.
  19. Iqbal S., El-Khoueiry A.B., Yang D. et al. A phase II study of capecitabine-oxaliplatin and cetuximab in patients with advanced/metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma. J. Clin. Oncol. 2012; 30 (Suppl.): abstr. 4096.
  20. Van Cutsem E., de Haas S., Kang Y.K. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J. Clin. Oncol. 2012; 30: 2119.
  21. Yi J.H., Lee J. et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br. J. Cancer. 2012; 106: 1469.
  22. Sun W., Powell M., O'Dwyer P.J. et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J. Clin. Oncol. 2010; 28: 2947.
  23. Park Y.S., Hwang H.S., Park H.J. et al. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum. Pathol. 2012; 43: 413.
  24. Gravalos C., Jimeno A. et al. HER2 in gastric cancer:a new prognostic factor and a novel therapeutic target. Ann. Oncol. 2008; 19: 1523-9.
  25. Hidis C.A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 2007; 357: 39-51.
  26. Tanner M., Hollmen M., Junttila T.T. et al. Amplification of HER2 in gastric carcinoma:association with Topoisomerase 2 alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 2010; 16: 273-8.
  27. Fujimoto-Ouchi K., Sekiguchi F., Yasuno H. et al. Antitumor activity of Trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother. Pharmacol. 2007; 59: 795-805.
  28. Bang Y., Chung H., Xu J. et al. Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial (abstract). J. Clin. Oncol. 2009; 27: 215s.
  29. Bang Y.J., Van Cutsem E., Feyereislova A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376 (9742): 687-97.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.